Synopsis
Interpret ER, PR and HER2 as predictive tumour biomarkers, obtain all three without avoidable delay, and connect results to endocrine and HER2-directed treatment decisions.
- NICE recommends assessing ER, PR and HER2 simultaneously at the initial histopathological diagnosis of every invasive breast cancer so results are ready for the first treatment discussion.
- ER and PR are nuclear hormone receptors. Positivity supports potential benefit from endocrine manipulation, but treatment choice still depends on menopausal status, recurrence risk, comorbidity and patient preference.
- HER2 overexpression or gene amplification identifies a biologically distinct group that may benefit from HER2-directed treatment; equivocal laboratory results need the validated reflex pathway, not a clinical guess.
Reasoning priorities
Determine whether the invasive tumour expresses the oestrogen receptor and may benefit from endocrine treatment.
Interpret the reported proportion and laboratory category under the validated pathology method. A result must be linked to invasive tumour tissue, not inferred from morphology.
Worked reasoning
Illustrative worked example: a 47-year-old has a 32 mm grade 3 invasive carcinoma, a biopsy-positive ipsilateral axillary node and no distant disease on staging; the first multidisciplinary meeting is in seven days.
- The team confirmed viable invasive tumour in the correctly labelled core and requested ER, PR and HER2 simultaneously at initial histopathological diagnosis.
- The laboratory reported ER-positive staining in 80% of invasive cells, PR-positive staining in 30%, and a HER2-positive result confirmed through its validated testing pathway. These are illustrative results; the anatomical extent remained cT2N1M0.
- At the meeting, the clinicians combined this biology with the node-positive extent, fitness and the patient's preferences and agreed oncology-led neoadjuvant systemic treatment with a HER2-directed component, followed by response-guided surgical planning. Endocrine treatment was retained in the subsequent plan because the tumour was ER-positive.
- The oncology assessment was completed, the planned cardiac assessment showed function acceptable for the proposed treatment, and consent documented both the HER2-related plan and later endocrine discussion.
- At the next team review, all three signed receptor results and the oncology treatment-start record were available; treatment had begun and no unresolved equivocal assay was delaying care. This observed process outcome shows why parallel profiling mattered without claiming receptors alone determined the whole plan.